Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.
Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.
Researchers at Yale Cancer Center and Yale Medicine have identified the critical target of new immune-checkpoint therapies: subsets of immune cells called tissue resident memory (TRM) T cells. In the same research, scientists also found that individual metastatic cancer lesions contain unique sets of TRM cells.
To better understand how cancer initiates and spreads, Yale associate professor of pathology Qin Yan turned to the field of epigenetics, which examines changes in the expression of genes and proteins that do not affect the underlying genetic codes.
The regular use of aspirin lowers the risk for pancreatic cancer by almost 50 percent, a new study in China led by the Yale School of Public Health finds.
A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.
Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.
Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses major targeted agents currently being studied in the treatment of patients with bladder cancer.
Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the impact that immunotherapy has had on the frontline treatment of patients with lung cancer.
Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses the recent explosion of immunotherapy research in the treatment landscape of bladder cancer.
Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses current treatment approaches for patients with human pappillomavirus (HPV)-positive head and neck cancer, as well as potential changes for those regimens.
Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.
Daniel P. Petrylak, MD, sheds light on the emerging roles of both immunotherapy and targeted agents in the treatment of patients with bladder cancer.
Lajos Pusztai, MD, DPhil, discusses findings that suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer.
Erin Wysong Hofstatter, MD, associate professor, co-director, Cancer Genetics and Prevention Program, Yale Cancer Center, discusses what impact the advancements with molecular testing have had on the identification of genetic abnormalities in patients with breast cancer.
Marcus Bosenberg, MD, PhD, associate professor of dermatology and pathology, Yale University, discusses mouse models for testing immunotherapies.
PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.
A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer with brain metastases to determine the best option for treatment.
Pooled data from ten universities finds added benefit from radiation boost among patients with negative margins following breast-conserving surgery.
In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.
The association between provider case volume and outcomes has long been suggested in cancer care.
Brigid Killelea, MD, MPH, FACS, associate professor of surgery (oncology), Yale Cancer Center, discusses the potential of nipple-sparing mastectomy for women who undergo surgery for breast cancer.
Anees B. Chagpar, MD, associate professor of Surgery (Oncology), director of The Breast Center at Smilow Cancer Hospital at Yale-New Haven, Yale Cancer Center, explains some of the most discussed topics in breast cancer. Chagpar was recently the chair at the State of the Science Summit on Breast Cancer held Sept. 15.
Barbara A. Burtness, MD, discussed the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.
Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.
Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.
Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.
Daniel P. Petrylak, MD, professor of Medicine, Yale Cancer Center, discusses his vision for radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer and how it integrates with chemotherapy and other agents for treatment of this patient population.
Vincent T. DeVita Jr, MD, discusses his insights into the operations of the FDA and the National Cancer Institute will hold a special appeal for oncology specialists and healthcare providers in his book, "The Death of Cancer."
Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.